

Companion Diagnostics for Oncology Market Size, Share & Trends Analysis Report By Products and Services (Assays, Kits, and Reagents, Software and Services), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS)), By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma, Others), By End-User (Pharmaceutical and Biopharmaceutical Companies, Laboratories, Contract Research Organizations, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-03-15 | 0 pages | Straits Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Global Site License \$5500.00

Report description:

Companion Diagnostics for Oncology Market Analysis and Insights

The Companion Diagnostics for Oncology Market size is anticipated to reach USD 2.96 Billion in 2022 and it is projected to reach USD 18.80 Billion by 2031, growing at a CAGR of % during the forecast period.

The Global Companion Diagnostics for Oncology Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Companion Diagnostics for Oncology Market growth, Size report provides a comprehensive analysis of the Healthcare IT industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Experts, Companion Diagnostics for Oncology Market includes major suppliers & Independent Consultants among others.
Global Market Scope and Companion Diagnostics for Oncology Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Companion Diagnostics for Oncology Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Companion Diagnostics for Oncology Market Country Level Analysis

The Global Companion Diagnostics for Oncology Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Companion Diagnostics for Oncology Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Companion Diagnostics for Oncology Market

Some of the other major highlights of the demand for Companion Diagnostics for Oncology Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Companion Diagnostics for Oncology Market during the forecast period.

Qiagen N.V.

F. Hoffmann La Roche Ltd

Agilent Technologies

Thermo Fisher Scientific

Abbott

Amoy diagnostics

BioMérieux SA

Archerdx

Illumina, Inc.

Foundation Medicine, Inc.

Market Segmentation

The Global Companion Diagnostics for Oncology Market Share, Demand provides the most up-to-date Healthcare IT industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

By Products and Services

Assays, Kits, and Reagents

Software and Services

By Technology

Polymerase Chain Reaction (PCR)

Next-Generation Sequencing (NGS)

By Indication

Breast Cancer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Lung Cancer
Colorectal Cancer
Gastric Cancer
Melanoma
Others

By End-User

Pharmaceutical and Biopharmaceutical Companies
Laboratories
Contract Research Organizations
Others

Regions Coverd

North America

U.S.
Canada

Europe

U.K.
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC

China
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Rest of Asia-Pacific

Middle East and Africa

UAE

Turkey

Saudi Arabia

South Africa

Egypt

Nigeria

Rest of MEA

LATAM

Brazil

Mexico

Argentina

Chile

Colombia

Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

- 1 Executive Summary
- 2 Research Scope & Segmentation
 - 2.1 Research Objectives
 - 2.2 Limitations & Assumptions
 - 2.3 Market Scope & Segmentation
 - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
 - 3.1 Emerging Regions / Countries
 - 3.2 Emerging Companies
 - 3.3 Emerging Applications / End Use
- 4 Market Trends
 - 4.1 Drivers
 - 4.2 Market Warning Factors
 - 4.3 Latest Macro Economic Indicators

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.4 Geopolitical Impact
- 4.5 Technology Factors
- 5 Market Assessment
 - 5.1 Porters Five Forces Analysis
 - 5.2 Value Chain Analysis
- 6 Global Companion Diagnostics for Oncology Market Size Analysis
 - 6.1 By Products and Services
 - 6.1.1 Assays, Kits, and Reagents
 - 6.1.2 Software and Services
 - 6.2 By Technology
 - 6.2.1 Polymerase Chain Reaction (PCR)
 - 6.2.2 Next-Generation Sequencing (NGS)
 - 6.3 By Indication
 - 6.3.1 Breast Cancer
 - 6.3.2 Lung Cancer
 - 6.3.3 Colorectal Cancer
 - 6.3.4 Gastric Cancer
 - 6.3.5 Melanoma
 - 6.3.6 Others
 - 6.4 By End-User
 - 6.4.1 Pharmaceutical and Biopharmaceutical Companies
 - 6.4.2 Laboratories
 - 6.4.3 Contract Research Organizations
 - 6.4.4 Others
- 7 North America Market Analysis
 - 7.1 By Products and Services
 - 7.1.1 Assays, Kits, and Reagents
 - 7.1.2 Software and Services
 - 7.2 By Technology
 - 7.2.1 Polymerase Chain Reaction (PCR)
 - 7.2.2 Next-Generation Sequencing (NGS)
 - 7.3 By Indication
 - 7.3.1 Breast Cancer
 - 7.3.2 Lung Cancer
 - 7.3.3 Colorectal Cancer
 - 7.3.4 Gastric Cancer
 - 7.3.5 Melanoma
 - 7.3.6 Others
 - 7.4 By End-User
 - 7.4.1 Pharmaceutical and Biopharmaceutical Companies
 - 7.4.2 Laboratories
 - 7.4.3 Contract Research Organizations
 - 7.4.4 Others
 - 7.4 U.S.
 - 7.5 Canada
- 8 Europe Market Analysis
 - 8.1 By Products and Services

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.1.1 Assays, Kits, and Reagents
- 8.1.2 Software and Services
- 8.2 By Technology
 - 8.2.1 Polymerase Chain Reaction (PCR)
 - 8.2.2 Next-Generation Sequencing (NGS)
- 8.3 By Indication
 - 8.3.1 Breast Cancer
 - 8.3.2 Lung Cancer
 - 8.3.3 Colorectal Cancer
 - 8.3.4 Gastric Cancer
 - 8.3.5 Melanoma
 - 8.3.6 Others
- 8.4 By End-User
 - 8.4.1 Pharmaceutical and Biopharmaceutical Companies
 - 8.4.2 Laboratories
 - 8.4.3 Contract Research Organizations
 - 8.4.4 Others
- 8.4 U.K.
- 8.5 Germany
- 8.6 France
- 8.7 Spain
- 8.8 Italy
- 8.9 Russia
- 8.10 Nordic
- 8.11 Benelux
- 8.12 Rest of Europe
- 9 APAC Market Analysis
 - 9.1 By Products and Services
 - 9.1.1 Assays, Kits, and Reagents
 - 9.1.2 Software and Services
 - 9.2 By Technology
 - 9.2.1 Polymerase Chain Reaction (PCR)
 - 9.2.2 Next-Generation Sequencing (NGS)
 - 9.3 By Indication
 - 9.3.1 Breast Cancer
 - 9.3.2 Lung Cancer
 - 9.3.3 Colorectal Cancer
 - 9.3.4 Gastric Cancer
 - 9.3.5 Melanoma
 - 9.3.6 Others
 - 9.4 By End-User
 - 9.4.1 Pharmaceutical and Biopharmaceutical Companies
 - 9.4.2 Laboratories
 - 9.4.3 Contract Research Organizations
 - 9.4.4 Others
 - 9.4 China
 - 9.5 Korea

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.6 Japan
- 9.7 India
- 9.8 Australia
- 9.9 Taiwan
- 9.10 South East Asia
- 9.11 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
 - 10.1 By Products and Services
 - 10.1.1 Assays, Kits, and Reagents
 - 10.1.2 Software and Services
 - 10.2 By Technology
 - 10.2.1 Polymerase Chain Reaction (PCR)
 - 10.2.2 Next-Generation Sequencing (NGS)
 - 10.3 By Indication
 - 10.3.1 Breast Cancer
 - 10.3.2 Lung Cancer
 - 10.3.3 Colorectal Cancer
 - 10.3.4 Gastric Cancer
 - 10.3.5 Melanoma
 - 10.3.6 Others
 - 10.4 By End-User
 - 10.4.1 Pharmaceutical and Biopharmaceutical Companies
 - 10.4.2 Laboratories
 - 10.4.3 Contract Research Organizations
 - 10.4.4 Others
 - 10.4 UAE
 - 10.5 Turkey
 - 10.6 Saudi Arabia
 - 10.7 South Africa
 - 10.8 Egypt
 - 10.9 Nigeria
 - 10.10 Rest of MEA
- 11 LATAM Market Analysis
 - 11.1 By Products and Services
 - 11.1.1 Assays, Kits, and Reagents
 - 11.1.2 Software and Services
 - 11.2 By Technology
 - 11.2.1 Polymerase Chain Reaction (PCR)
 - 11.2.2 Next-Generation Sequencing (NGS)
 - 11.3 By Indication
 - 11.3.1 Breast Cancer
 - 11.3.2 Lung Cancer
 - 11.3.3 Colorectal Cancer
 - 11.3.4 Gastric Cancer
 - 11.3.5 Melanoma
 - 11.3.6 Others
 - 11.4 By End-User

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.4.1 Pharmaceutical and Biopharmaceutical Companies
- 11.4.2 Laboratories
- 11.4.3 Contract Research Organizations
- 11.4.4 Others
- 11.4 Brazil
- 11.5 Mexico
- 11.6 Argentina
- 11.7 Chile
- 11.8 Colombia
- 11.9 Rest of LATAM
- 12 Competitive Landscape
- 12.1 Global Companion Diagnostics for Oncology Market Share By Players
- 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
- 13.1 American International Industries (GIGI)
- 13.1.1 Overview
- 13.1.2 Business Information
- 13.1.3 Revenue
- 13.1.4 ASP
- 13.1.5 Swot Analysis
- 13.1.6 Recent Developments
- 13.2 F. Hoffmann La Roche Ltd
- 13.3 Agilent Technologies
- 13.4 Thermo Fisher Scientific
- 13.5 Abbott
- 13.6 Amoy diagnostics
- 13.7 BioMérieux SA
- 13.8 Archerdx
- 13.9 Illumina, Inc.
- 13.10 Foundation Medicine, Inc.
- 14 Research Methodology
- 14.1 Research Data
- 14.1.1 Secondary Data
- 14.1.1.1 Major secondary sources
- 14.1.1.2 Key data from secondary sources
- 14.1.2 Primary Data
- 14.1.2.1 Key data from primary sources
- 14.1.2.2 Breakdown of primaries
- 14.1.3 Secondary And Primary Research
- 14.1.3.1 Key industry insights
- 14.2 Market Size Estimation
- 14.2.1 Bottom-Up Approach
- 14.2.2 Top-Down Approach
- 14.2.3 Market Projection
- 14.3 Research Assumptions
- 14.3.1 Assumptions
- 14.4 Limitations

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.5 Risk Assessment
- 15 Appendix
 - 15.1 Discussion Guide
 - 15.2 Customization Options
 - 15.3 Related Reports
- 16 Disclaimer

Companion Diagnostics for Oncology Market Size, Share & Trends Analysis Report By Products and Services (Assays, Kits, and Reagents, Software and Services), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS)), By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Melanoma, Others), By End-User (Pharmaceutical and Biopharmaceutical Companies, Laboratories, Contract Research Organizations, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-03-15 | 0 pages | Straits Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2026-02-21
		Signature	